Mar 15, 2023 / 01:00PM GMT
David M. Stack - Pacira BioSciences, Inc. - Chairman & CEO
(technical difficulty) given the fact that we have some opportunities there, frankly, for example, if they're not doing procedures and patients require pain control, then we have other assets in our portfolio that would be positively impacted by that. And so, it's a combination of all of those things that gave us the guidance that we think is appropriately conservative, given everything that's going on in the macro environment.
Questions and Answers:
Unidentified Analyst -Great. Since the earnings call David, there had done also I think post your commentaries around 340B, especially, in January, I think that's where we've gotten some of the most calls on trying to understand these dynamics of 340B, non-340B, what is the mix? What is the impact? And then, of course, leads into no pain act. So could you maybe take us through that and help us understand this volume growth in the context of this?
David M. Stack - Pacira BioSciences, Inc. - Chairman & CEO
Trustpilot
